Solve Therapeutics Raises $120M in Oversubscribed Funding Round

Why It Matters

The infusion bolsters Solve's capacity to advance its ADC candidates toward market, underscoring strong investor confidence in next‑generation cancer therapeutics and positioning the company for potential partnerships or a future public offering.

Deal Summary

Solve Therapeutics, a clinical‑stage biotech focused on antibody‑drug conjugates, announced a $120 million financing to accelerate its pipeline and CloakLink linker platform. The round was led by Yosemite with participation from multiple venture and strategic investors, expanding the company’s total capital raised to $321 million.